After reporting promising efficacy signals in the ongoing phase II study on patients with the eye disease RVO, Annexin Pharmaceuticals now has a stronger position in licensing and partnership discussions. To finance continued activities, the company also plans to conduct a rights issue of approximately SEK 45 million, with parts of both the board and management intending to participate. BioStock reached out to CEO Anders Haegerstrand for a comment. 

Read the interview with CEO Anders Haegerstrand here:

https://www.biostock.se/en/2024/04/annexin-towards-completion-of-phase-ii-study-and-share-issue/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

https://news.cision.com/annexin-pharmaceuticals-ab/r/biostock-annexin-towards-completion-of-phase-ii-study-and-share-issue,c3963744

(c) 2024 Cision. All rights reserved., source Press Releases - English